MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• The durability of survival observed in induction-treated subset, together with evidence of immune activation, is central to how MiNK, potential partners, and the FDA evaluate meaningful outcomes and will shape next phase of development

  60% confidence

• Disease control and longer-term survival observed in a subset of patients support further study of this approach despite the study not meeting its primary endpoint of ORR

  60% confidence

• This study reinforces the potential of agenT-797 as an immune orchestrator capable of re-engaging anti-tumor immunity in highly resistant cancers

  60% confidence

• Sequencing of treatment may be as important as the treatment itself, as longer survival without disease progression was observed in patients who received an early immune-priming step before the full regimen

  60% confidence

Cited in these Via News reports

• AI-Designed Antibody BD200 Outperforms Standard Treatments in Drug-Resistant Cancers, Marking First Clinical Trial for Machine Learning Platform →
• AI-Designed Cancer Drug BD200 Defeats Resistant Tumors, Outperforms Marketed Antibodies →